PD-L1 expression
|
Gastroesophageal Junction Adenocarcinoma
|
PD-L1 expression
|
Gastroesophageal Junction Adenocarcinoma
|
nivolumab + ipilimumab Sensitive: C1 - Off-label
ASCO 2022 - 3 days (NewC1)
|
nivolumab + ipilimumab Sensitive: C1 - Off-label
ASCO 2022 - 3 days - (New C3)
|
PD-L1 expression
|
Gastric Cancer
|
PD-L1 expression
|
Gastric Cancer
|
durvalumab + AZD6738 Sensitive: C3 – Early Trials
ASCO 2022 - 3 days (NewC3)
|
durvalumab + AZD6738 Sensitive: C3 – Early Trials
ASCO 2022 - 3 days - (New C3)
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
tislelizumab + ZW25 Sensitive: C3 – Early Trials
ASCO 2022 - 3 days (NewC3)
|
tislelizumab + ZW25 Sensitive: C3 – Early Trials
ASCO 2022 - 3 days - (New C3)
|
HER-2 positive
|
Gastric Cancer
|
HER-2 positive
|
Gastric Cancer
|
tislelizumab + ZW25 Sensitive: C3 – Early Trials
ASCO 2022 - 3 days (NewC3)
|
tislelizumab + ZW25 Sensitive: C3 – Early Trials
ASCO 2022 - 3 days - (New C3)
|
HER-2 expression
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 expression
|
Gastroesophageal Junction Adenocarcinoma
|
KN026 Sensitive: C3 – Early Trials
ASCO 2022 - 3 days (NewC3)
|
KN026 Sensitive: C3 – Early Trials
ASCO 2022 - 3 days - (New C3)
|
HER-2 expression
|
Gastric Cancer
|
HER-2 expression
|
Gastric Cancer
|
KN026 Sensitive: C3 – Early Trials
ASCO 2022 - 3 days (NewC3)
|
KN026 Sensitive: C3 – Early Trials
ASCO 2022 - 3 days - (New C3)
|
VSNL1 underexpression + CD44 underexpression
|
Gastric Cancer
|
VSNL1 underexpression + CD44 underexpression
|
Gastric Cancer
|
paclitaxel Sensitive: B - Late Trials
Sci Rep - 1 week (NewB)
|
paclitaxel Sensitive: B - Late Trials
Sci Rep - 1 week - (New B)
|
CLDN18.2 positive
|
Gastric Cancer
|
CLDN18.2 positive
|
Gastric Cancer
|
CT041 Sensitive: C2 – Inclusion Criteria
Nat Med - 2 weeks (NewC2)
|
CT041 Sensitive: C2 – Inclusion Criteria
Nat Med - 2 weeks - (New C3)
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
trastuzumab Sensitive: A1 - Approval
|
trastuzumab Sensitive: A1 - Approval
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
nivolumab Sensitive: A1 - Approval
|
nivolumab Sensitive: A1 - Approval
|
No biomarker
|
Gastric Cancer
|
No biomarker
|
Gastric Cancer
|
nivolumab Sensitive: A1 - Approval
|
nivolumab Sensitive: A1 - Approval
|
No biomarker
|
Gastric Adenocarcinoma
|
No biomarker
|
Gastric Adenocarcinoma
|
cisplatin + 5-fluorouracil + docetaxel Sensitive: A1 - Approval
|
cisplatin + 5-fluorouracil + docetaxel Sensitive: A1 - Approval
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
cisplatin + 5-fluorouracil + docetaxel Sensitive: A1 - Approval
|
cisplatin + 5-fluorouracil + docetaxel Sensitive: A1 - Approval
|
HER-2 positive
|
Gastric Cancer
|
HER-2 positive
|
Gastric Cancer
|
fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval
|
fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval
|
fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval
|
No biomarker
|
Gastric Cancer
|
No biomarker
|
Gastric Cancer
|
TPF Sensitive: A1 - Approval
|
TPF Sensitive: A1 - Approval
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
TPF Sensitive: A1 - Approval
|
TPF Sensitive: A1 - Approval
|
HER-2 positive
|
Gastric Cancer
|
HER-2 positive
|
Gastric Cancer
|
pembrolizumab + trastuzumab Sensitive: A1 - Approval
|
pembrolizumab + trastuzumab Sensitive: A1 - Approval
|
HER-2 negative + PD-L1 expression
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 negative + PD-L1 expression
|
Gastroesophageal Junction Adenocarcinoma
|
nivolumab Sensitive: A1 - Approval
|
nivolumab Sensitive: A1 - Approval
|
HER-2 negative + PD-L1 expression
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 negative + PD-L1 expression
|
Gastroesophageal Junction Adenocarcinoma
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
HER-2 negative + PD-L1 expression
|
Gastric Cancer
|
HER-2 negative + PD-L1 expression
|
Gastric Cancer
|
nivolumab Sensitive: A1 - Approval
|
nivolumab Sensitive: A1 - Approval
|
HER-2 overexpression
|
Gastric Cancer
|
HER-2 overexpression
|
Gastric Cancer
|
trastuzumab Sensitive: A1 - Approval
|
trastuzumab Sensitive: A1 - Approval
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Gastric Cancer
|
HER-2 overexpression
|
Gastric Cancer
|
Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Gastric Cancer
|
HER-2 overexpression
|
Gastric Cancer
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Gastric Cancer
|
HER-2 overexpression
|
Gastric Cancer
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Gastric Cancer
|
HER-2 overexpression
|
Gastric Cancer
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Gastric Cancer
|
HER-2 overexpression
|
Gastric Cancer
|
Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
trifluridine/tipiracil Sensitive: A1 - Approval
|
trifluridine / tipiracil Sensitive: A1 - Approval
|
No biomarker
|
Gastric Cancer
|
No biomarker
|
Gastric Cancer
|
trifluridine/tipiracil Sensitive: A1 - Approval
|
trifluridine / tipiracil Sensitive: A1 - Approval
|
No biomarker
|
Gastric Cancer
|
No biomarker
|
Gastric Cancer
|
ramucirumab Sensitive: A1 - Approval
|
ramucirumab Sensitive: A1 - Approval
|
No biomarker
|
Gastric Cancer
|
No biomarker
|
Gastric Cancer
|
capecitabine Sensitive: A1 - Approval
|
capecitabine Sensitive: A1 - Approval
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
ramucirumab Sensitive: A1 - Approval
|
ramucirumab Sensitive: A1 - Approval
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 overexpression
|
Gastroesophageal Junction Adenocarcinoma
|
trastuzumab Sensitive: A1 - Approval
|
trastuzumab Sensitive: A1 - Approval
|
HER-2 overexpression
|
Gastric Cancer
|
HER-2 overexpression
|
Gastric Cancer
|
Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 positive
|
Gastric Cancer
|
HER-2 positive
|
Gastric Cancer
|
Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval
|
MSI-H/dMMR
|
Gastric Cancer
|
MSI-H/dMMR
|
Gastric Cancer
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
HER-2 overexpression
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 overexpression
|
Gastroesophageal Junction Adenocarcinoma
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 overexpression
|
Gastroesophageal Junction Adenocarcinoma
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 overexpression
|
Gastroesophageal Junction Adenocarcinoma
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
pembrolizumab + trastuzumab Sensitive: A1 - Approval
|
pembrolizumab + trastuzumab Sensitive: A1 - Approval
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
disitamab vedotin Sensitive: A1 - Approval
|
disitamab vedotin Sensitive: A1 - Approval
|
No biomarker
|
Gastric Cancer
|
No biomarker
|
Gastric Cancer
|
disitamab vedotin Sensitive: A1 - Approval
|
disitamab vedotin Sensitive: A1 - Approval
|
HER-2 positive
|
Gastric Cancer
|
HER-2 positive
|
Gastric Cancer
|
trastuzumab Sensitive: A2 - Guideline
|
trastuzumab Sensitive: A2 - Guideline
|
HER-2 negative
|
Gastric Cancer
|
HER-2 negative
|
Gastric Cancer
|
cisplatin + capecitabine Sensitive: A2 - Guideline
|
cisplatin + capecitabine Sensitive: A2 - Guideline
|
HER-2 negative
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 negative
|
Gastroesophageal Junction Adenocarcinoma
|
cisplatin + capecitabine Sensitive: A2 - Guideline
|
cisplatin + capecitabine Sensitive: A2 - Guideline
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
DOF Sensitive: A2 - Guideline
|
DOF Sensitive: A2 - Guideline
|
No biomarker
|
Gastric Cancer
|
No biomarker
|
Gastric Cancer
|
TCF Sensitive: A2 - Guideline
|
TCF Sensitive: A2 - Guideline
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
TCF Sensitive: A2 - Guideline
|
TCF Sensitive: A2 - Guideline
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
FP Sensitive: A2 - Guideline
|
FP Sensitive: A2 - Guideline
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
CaT Sensitive: A2 - Guideline
|
CaT Sensitive: A2 - Guideline
|
No biomarker
|
Gastric Cancer
|
No biomarker
|
Gastric Cancer
|
FP Sensitive: A2 - Guideline
|
FP Sensitive: A2 - Guideline
|
No biomarker
|
Gastric Cancer
|
No biomarker
|
Gastric Cancer
|
FOLFIRI Sensitive: A2 - Guideline
|
FOLFIRI Sensitive: A2 - Guideline
|
HER-2 negative
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 negative
|
Gastroesophageal Junction Adenocarcinoma
|
CAPOX Sensitive: A2 - Guideline
|
CAPOX Sensitive: A2 - Guideline
|
HER-2 negative
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 negative
|
Gastroesophageal Junction Adenocarcinoma
|
5-fluorouracil + oxaliplatin Sensitive: A2 - Guideline
|
5-fluorouracil + oxaliplatin Sensitive: A2 - Guideline
|
HER-2 negative
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 negative
|
Gastroesophageal Junction Adenocarcinoma
|
FP Sensitive: A2 - Guideline
|
FP Sensitive: A2 - Guideline
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
capecitabine Sensitive: A2 - Guideline
|
capecitabine Sensitive: A2 - Guideline
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
5-fluorouracil Sensitive: A2 - Guideline
|
5-fluorouracil Sensitive: A2 - Guideline
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
DP Sensitive: A2 - Guideline
|
DP Sensitive: A2 - Guideline
|
No biomarker
|
Gastric Cancer
|
No biomarker
|
Gastric Cancer
|
5-fluorouracil Sensitive: A2 - Guideline
|
5-fluorouracil Sensitive: A2 - Guideline
|
No biomarker
|
Gastric Cancer
|
No biomarker
|
Gastric Cancer
|
5-fluorouracil + irinotecan Sensitive: A2 - Guideline
|
5-fluorouracil + irinotecan Sensitive: A2 - Guideline
|
HER-2 negative
|
Gastric Cancer
|
HER-2 negative
|
Gastric Cancer
|
cisplatin + 5-fluorouracil Sensitive: A2 - Guideline
|
cisplatin + 5-fluorouracil Sensitive: A2 - Guideline
|
HER-2 negative
|
Gastric Cancer
|
HER-2 negative
|
Gastric Cancer
|
CAPOX Sensitive: A2 - Guideline
|
CAPOX Sensitive: A2 - Guideline
|
HER-2 negative
|
Gastric Cancer
|
HER-2 negative
|
Gastric Cancer
|
5-fluorouracil + oxaliplatin Sensitive: A2 - Guideline
|
5-fluorouracil + oxaliplatin Sensitive: A2 - Guideline
|
No biomarker
|
Gastric Cancer
|
No biomarker
|
Gastric Cancer
|
paclitaxel + 5-fluorouracil Sensitive: A2 - Guideline
|
paclitaxel + 5-fluorouracil Sensitive: A2 - Guideline
|
No biomarker
|
Gastric Cancer
|
No biomarker
|
Gastric Cancer
|
paclitaxel + capecitabine Sensitive: A2 - Guideline
|
paclitaxel + capecitabine Sensitive: A2 - Guideline
|
TMB-H
|
Gastric Cancer
|
TMB-H
|
Gastric Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
No biomarker
|
Gastric Cancer
|
No biomarker
|
Gastric Cancer
|
FLOT Sensitive: A2 - Guideline
|
FLOT Sensitive: A2 - Guideline
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
FLOT Sensitive: A2 - Guideline
|
FLOT Sensitive: A2 - Guideline
|
HER-2 positive
|
Gastroesophageal Cancer
|
HER-2 positive
|
Gastroesophageal Cancer
|
trastuzumab Sensitive: A2 - Guideline
|
trastuzumab Sensitive: A2 - Guideline
|
PD-L1 expression
|
Gastric Adenocarcinoma
|
PD-L1 expression
|
Gastric Adenocarcinoma
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
No biomarker
|
Gastric Cancer
|
No biomarker
|
Gastric Cancer
|
cisplatin + irinotecan Sensitive: A2 - Guideline
|
cisplatin + irinotecan Sensitive: A2 - Guideline
|
No biomarker
|
Gastric Cancer
|
No biomarker
|
Gastric Cancer
|
irinotecan Sensitive: A2 - Guideline
|
irinotecan Sensitive: A2 - Guideline
|
No biomarker
|
Gastric Cancer
|
No biomarker
|
Gastric Cancer
|
paclitaxel Sensitive: A2 - Guideline
|
paclitaxel Sensitive: A2 - Guideline
|
No biomarker
|
Gastric Cancer
|
No biomarker
|
Gastric Cancer
|
docetaxel Sensitive: A2 - Guideline
|
docetaxel Sensitive: A2 - Guideline
|
No biomarker
|
Gastric Cancer
|
No biomarker
|
Gastric Cancer
|
docetaxel + irinotecan Sensitive: A2 - Guideline
|
docetaxel + irinotecan Sensitive: A2 - Guideline
|
No biomarker
|
Gastric Cancer
|
No biomarker
|
Gastric Cancer
|
cisplatin + docetaxel Sensitive: A2 - Guideline
|
cisplatin + docetaxel Sensitive: A2 - Guideline
|
No biomarker
|
Gastric Cancer
|
No biomarker
|
Gastric Cancer
|
carboplatin + paclitaxel Sensitive: A2 - Guideline
|
carboplatin + paclitaxel Sensitive: A2 - Guideline
|
No biomarker
|
Gastric Cancer
|
No biomarker
|
Gastric Cancer
|
CAPOX Sensitive: A2 - Guideline
|
CAPOX Sensitive: A2 - Guideline
|
No biomarker
|
Gastric Cancer
|
No biomarker
|
Gastric Cancer
|
5-fluorouracil + oxaliplatin Sensitive: A2 - Guideline
|
5-fluorouracil + oxaliplatin Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Gastroesophageal Junction Adenocarcinoma
|
MSI-H/dMMR
|
Gastroesophageal Junction Adenocarcinoma
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
cisplatin + capecitabine Sensitive: A2 - Guideline
|
cisplatin + capecitabine Sensitive: A2 - Guideline
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
5-fluorouracil + irinotecan Sensitive: A2 - Guideline
|
5-fluorouracil + irinotecan Sensitive: A2 - Guideline
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
irinotecan Sensitive: A2 - Guideline
|
irinotecan Sensitive: A2 - Guideline
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
paclitaxel Sensitive: A2 - Guideline
|
paclitaxel Sensitive: A2 - Guideline
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
docetaxel Sensitive: A2 - Guideline
|
docetaxel Sensitive: A2 - Guideline
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
docetaxel + irinotecan Sensitive: A2 - Guideline
|
docetaxel + irinotecan Sensitive: A2 - Guideline
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
IP Sensitive: A2 - Guideline
|
IP Sensitive: A2 - Guideline
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
5-fluorouracil + oxaliplatin Sensitive: A2 - Guideline
|
5-fluorouracil + oxaliplatin Sensitive: A2 - Guideline
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
capecitabine + oxaliplatin Sensitive: A2 - Guideline
|
capecitabine + oxaliplatin Sensitive: A2 - Guideline
|
NTRK3 fusion
|
Gastroesophageal Junction Adenocarcinoma
|
NTRK3 fusion
|
Gastroesophageal Junction Adenocarcinoma
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Gastroesophageal Junction Adenocarcinoma
|
NTRK2 fusion
|
Gastroesophageal Junction Adenocarcinoma
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK1 fusion
|
Gastroesophageal Junction Adenocarcinoma
|
NTRK1 fusion
|
Gastroesophageal Junction Adenocarcinoma
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK3 fusion
|
Gastroesophageal Junction Adenocarcinoma
|
NTRK3 fusion
|
Gastroesophageal Junction Adenocarcinoma
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|